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| INTRODUCTION
Bronchiolitis obliterans syndrome (BOS) is a form of irreversible airflow obstruction and is a clinical manifestation of chronic allograft rejection following lung transplantation. 1, 2 Despite advances in the field, the 5-year mortality remains approximately 50% with the majority of post-transplant complications occurring after the first year being attributable to BOS/chronic allograft rejection. 1, 2 BOS is associated with numerous risk factors including medication noncompliance, cytomegalovirus infection, gastroesophageal reflux disease, acute cellular rejection, air pollution, and interstitial pneumonitis, and its development and progression are associated with a threefold increase in the risk of death at 3 years. [3] [4] [5] [6] [7] [8] [9] [10] [11] Currently, the presence and progression of BOS are primarily defined by spirometry, which can be variable from test to test and is partially effort dependent.
Our prior work in BOS following allogeneic hematopoietic stem cell transplantation (HSCT) demonstrated that airway remodeling in BOS is characterized by central airway dilation, and the degree of this dilation is associated with impairments in lung function and the progression of BOS. 12 We hypothesized that a similar phenomenon is present in patients following lung transplantation. Therefore, we performed an exploratory analysis of clinically acquired computed tomography (CT) scans and autopsies from a cohort of over 200 patients who underwent lung transplantation at our institution to assess the association between the presence and progression of BOS and quantitative CT measures of proximal airway and vessel morphology as well as their pathologic correlates.
| METHODS

| Subjects
All patients who received a cadaveric lung transplant at the Brigham and Women's Hospital (n=204) between December 1, 2002 and December 31, 2010 were included in this study. The medical records for each of these subjects were reviewed for availability of lung autopsy tissue, longitudinal measures of lung function, and clinically acquired CT scans of the chest available for analysis. CT scans and measures of lung function were included if they were acquired within 90 days of each other. In addition, patients with extensive interstitial disease on CT that did not allow for identification of 16 airways and vessels (eight for unilateral transplants) were excluded. The
Institutional Review Board at Brigham and Women's Hospital, Boston, MA, approved this study.
| Pulmonary function testing
Per the postlung transplantation protocol at our institution, spirometric measures of lung function (Morgan Scientific, Inc, Haverhill, MA, USA) are obtained at every lung transplant clinic visit without the administration of a short acting inhaled bronchodilator using standards published by the American Thoracic Society. 13 Lung function data collected for this study included forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC), and forced expiratory flow between 25% and 75% (FEF ).
Baseline FEV 1 value was defined as the average of the two highest post-transplant measurements obtained at least 3 weeks apart without bronchodilators. The presence of BOS was defined using baseline spirometry and using consensus criteria as previously described: BOS 
| CT scans
As discussed above, the clinical data of all subjects who had undergone lung transplantation during the specified time period were reviewed for CT scans of the chest that could be used for quantitative assessment. As anticipated with clinically acquired data, it was apparent that subjects had one of two types of CT scan available: Volumetric CT scans acquired with intravenous contrast for the detection of pulmonary embolism (CT pulmonary angiogram protocol-CTPA) and noncontrast nonvolumetric CT scans consisting of 1 mm axial slices spaced either every 1 or 2 cm, which are frequently described as highresolution CT (HRCT) scans. In addition, it was noted that no subject had more than one follow-up CTPA available, the presence of which would allow for the investigation of BOS progression over time. Thus, as this was an exploratory study, both groups were included, but due to the heterogeneity of the imaging data, specifically with regard to the technique for the longitudinal measurement of airway and vessel characteristics, they were analyzed separately as discussed below.
| Volumetric CT scan analysis
Subjects were included if they had a minimum of two clinically CTPA scans available for longitudinal airway/vessel analysis. If a subject had more than two of such CT scans, the two scans spanning the largest time interval were selected. Images were reconstructed using a high-spatial frequency algorithm with 1 mm-1.25 mm slice thickness at 1 mm intervals. Analysts who were blinded to the clinical diagnosis made the following measurements using the phase congruency method implemented via Airway Inspector (www.airwayinspector.
org) of the third-and fourth-generation B1 and B10 airways and adjoining vessels in the transplanted lung(s) airway internal lumen perimeter (PI), wall thickness, wall area percent (WA%:100* wall area/ total bronchial area), and airway lumen area (AI). [17] [18] [19] The vessel crosssectional area (CSA) of the vessels adjoining these airways was measured by upper thresholding the slice corresponding to the adjacent vessels with a cutoff level of −500 HU and isolating the vessel cross section using a connected components technique. The CSA was then computed by integrating the area of the pixels labeled as vessel. Note that in those with bilateral lung transplants, all measurements were made in both lungs and averaged. Additional measures performed included CT measured total lung volume, which was calculated as described previously. 20 Due to the small size of this cohort, subjects in it were categorized only as either controls or BOS cases based on the aforementioned spirometric criteria.
| Nonvolumetric CT scan-BOS progression analysis
Patients were included in this analysis if they had a noncontrast HRCT available at the time of, or prior to the diagnosis of BOS and two additional longitudinal noncontrast HRCT scans conducted after their baseline CT scan. If more than three noncontrast HRCT scans were available, then the CT scan closest to the baseline FEV 1 was utilized for scan 1, the latest available for scan 3, and the CT scan closest to the median days between these scans was used for CT 2. This cohort was initially divided into two groups as described above. In addition, in order to leverage the greater number of subjects and CT scans that were available for this cohort and to help further define the imaging findings associated with BOS progression, the BOS group was subdivided further into BOS nonprogressors (NP) (defined as those with spirometric improvement or <10% decline in FEV 1 between scan 2 and scan 3) (n=22) and BOS progressors (defined as those with a >10% decline in FEV 1 between scan 2 to scan 3) (n=24). In this cohort, because of the nonvolumetric (nonadjacent) spacing of the CT images, measurements of the same segmental airway and vessel could not be made reliably on all three of a subject's CT scans as was performed for the volumetric data. Therefore, based upon a technique used in prior studies, the airway and vessel measurements described in the analysis of volumetric CT scans above were instead performed on a total of 16 airways (eight for unilateral transplants) with four in each quadrant (i.e, the right and left upper lobes and the right and left lower lobes) and then averaged for each CT scan. These averages were then compared longitudinally.
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| Pathology
For the subgroup of subjects for whom autopsy samples were available, sequential sections of lung tissue were stained with hematoxylin and eosin, Masson's trichrome, and Verhoeff elastic stains. Two pathologists blinded to the clinical diagnosis evaluated the specimens utilizing the International Society of Heart Lung Transplant working formulation for the grading of pulmonary allograft rejection and arteriopathy. 16, 25 Allograft rejection and arteriopathy were graded as present or absent. In addition, proximal cartilaginous and small noncartilaginous peripheral airways were reviewed for the presence or absence of subepithelial fibrosis and/or intraluminal granulation tissue. 26, 27 Of note, the pathology subgroup represented subjects from both of the CT cohorts described above and subjects not included in the CT analysis. (Cary, NC, USA).
| Statistical analysis
| RESULTS
| Cohort
Ninety-four of the 204 (46.1%) subjects met our criteria for inclusion in the study. There were four subjects in the volumetric CTPA group that overlapped with the nonvolumetric noncontrast HRCT group.
There were five Subjects in the pathology group overlapped with the noncontrast HRCT group and two subjects overlapped with the CTPA group. Fifteen subjects (7.4%) in total were excluded for interstitial changes on CT that did not allow for airway and vessel measurements ( Figure 1 ). In total, 242 CT scans from 84 subjects were included in this study.
| Volumetric QCT analysis
Twenty-two of the 204 subjects (10.8%) had two or more volumetric CTPA scans available for airway and vascular analysis (Table 1A) .
None of the subjects in this group had significant enough interstitial disease to prevent airway and vessel measurements. 
| Nonvolumetric CT Scan-BOS progression analysis
Sixty-six subjects (32%) had three HRCT scans available for analysis (Table 1B) . Twenty patients were categorized as controls, 22 as BOS NP, and 24 as BOS progressors based on the criteria described above.
Fifteen subjects (7.4%) of this cohort were excluded for interstitial changes on CT that did not allow for airway and vessel measurements. At the time of the baseline scan (scan 1), there was no difference in the FEV 1 and A/V ratio between the 3 groups (P=NS and P=NS, respectively) ( Table 3 and Figure 3 ). With regard to progression over time, as expected based on their case definition, control subjects' FEV 1 remained unchanged between the three scans (P=NS) ( Table 3 and Figure 3) . Similarly, their A/V ratio did not change over time (P=NS) ( Table 3 and Figure 4 ).
Nonprogressor subjects' FEV 1 declined significantly between scans 1 and 2 (P<.001) and increased significantly between scan 2 and 3 (P<.001) ( Table 3 and Figure 3 ). There was no significant change in the A/V ratio between scans despite the observed changes in lung function (P=NS) ( Table 3 and Figure 4 ).
BOS progressor subjects demonstrated a significant decline in FEV 1 between scans 1 and 2 (P=.001) and between 2 and 3 (P<.001) (Table 3 and Figure 3 ). In addition, they had a significant increase in the A/V ratio between scan 1 and scan 2 (P<.001) and between scan 2 and 3 (P<.001) ( Table 3 and Figure 4 ).
There was no statistically significant difference in quantitative lung volume measurements between group's P=NS, data not shown. After adjustment for age, gender, and lung volumes, the differences in A/V ratio across groups remained statistically significant. We performed a subset analysis after removing the nine subjects who overlapped between the volumetric and pathology cohort and the nonvolumetric cohort, and there was no change in the statistical significance between groups, data not shown. Figure 5 represents a HRCT imaging of a subject before and after the diagnosis of BOS (BOS progressor) and demonstrates the observed airway dilation and a reduction in vascular cross-sectional area.
| Pathologic analysis
Seventeen of the 204 subjects (8.3%) of our cohort had archival autopsy tissue available for histopathologic analysis. Baseline characteristics of these subjects and the clinical cause of death as reported on the autopsy report are depicted in Table 1C and Table 4 Proximal cartilaginous airways and small non-cartilaginous airways were inadequately sampled in one control and 2 BOS subjects.
F I G U R E 1 Flow sheet inclusion criteria
A greater percentage of BOS subjects demonstrated proximal airway fibrosis as compared to controls, (P=.003). Although more BOS subjects had proximal and distal arteriopathy as compared to the controls, this difference did not reach statistical significance (Table 5 ). Figure 6 is a representative image of proximal airway and vessel (generation<5) fibrosis in a patient with BOS as compared to a control.
| DISCUSSION
In this retrospective exploratory examination of clinically acquired data from lung transplant recipients at our institution, we found CT evidence of bronchiectatic dilation of the large airways in subjects with BOS that is proportional to the degree of expiratory airflow obstruction. More specifically, using a method which is analogous to the visual assessment of such airway disease, we employed an objective measure of airway lumen area and its ratio to the cross-sectional area of the adjacent blood vessel and found it to be increased in those These results are consistent with our previous investigation of BOS following HSCT where we found that airway remodeling is characterized by lumen dilation in proportion to decrements in the FEV 1 .
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Other, visual analysis-based radiologic studies have demonstrated that the development of BOS following lung transplantation is associated with evidence of decreased peripheral vascular markings, bronchiectatic dilation of the central airways, and gas trapping on expiratory imaging. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] However, to this point, quantitative methods for image analysis in this population have largely focused on expiratory gas trapping, which has been reported to be sensitive for the detection of BOS and its subsequent progression, with limited investigation into any change that may occur in the proximal airways. 38, 39 In this study, we also found significant histopathologic evidence of central airway fibrosis, and possible, but not significant, evidence 27 This group hypothesized that perivascular inflammation involving the allograft pulmonary arteries, veins, capillaries, and the airway microcirculation led to pulmonary vascular remodeling, parenchymal fibrosis, and allograft airway injury. 27 While many of our findings are significant, our data consist of a retrospective assessment of clinically acquired data and as such there may be confounding related to the timing at which patients received a CT scan or autopsy. Additional potential confounders include the presence or absence of restrictive allograft syndrome in our cohort. This syndrome has been recently identified as a form of chronic allograft dysfunction that is associated with interstitial lung disease and a lower survival. [46] [47] [48] Patients with significant interstitial lung disease were excluded from our analysis if it prevented the airways and vessels from being identified and measured. As restrictive allograft syndrome and BOS can overlap, this exclusion may mean that our study cohort is not representative of all patients with BOS. As a result of low numbers in our CTPA and pathology cohorts, there was also overlap between all three cohorts. To account for this, we reanalyzed our data removing the nine subjects from the noncontrast HRCT cohort who overlapped with the CTPA and Pathology cohort. There was no change in the significance of our reported results, data not shown. 
